CD2 Immunobiology

被引:84
作者
Binder, Christian [1 ,2 ]
Cvetkovski, Filip [2 ]
Sellberg, Felix [1 ,2 ]
Berg, Stefan [2 ]
Visbal, Horacio Paternina [1 ,2 ]
Sachs, David H. [2 ,3 ]
Berglund, Erik [2 ,4 ,5 ]
Berglund, David [1 ,2 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Sect Clin Immunol, Uppsala, Sweden
[2] ITB Med AB, Res & Dev, Stockholm, Sweden
[3] Columbia Univ, Dept Med, Columbia Ctr Translat Immunol, Med Ctr, New York, NY USA
[4] Karolinska Inst, Div Transplantat Surg, CLINTEC, Stockholm, Sweden
[5] Karolinska Univ Hosp, Dept Transplantat Surg, Stockholm, Sweden
来源
FRONTIERS IN IMMUNOLOGY | 2020年 / 11卷
关键词
CD2; CD58; LFA-3 (lymphocyte functional antigen-3); T cell activation; costimulation; costimulation blockade; Alefacept; siplizumab; T-CELL-RECEPTOR; ANTI-CD2; MONOCLONAL-ANTIBODY; NATURAL-KILLER-CELLS; PLASMA-MEMBRANE MICRODOMAINS; BONE-MARROW-TRANSPLANTATION; ADHESION MOLECULE CD2; CYTOPLASMIC DOMAIN; THYMIC SELECTION; CAPPING PROTEIN; SAFETY PROFILE;
D O I
10.3389/fimmu.2020.01090
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The glycoprotein CD2 is a costimulatory receptor expressed mainly on T and NK cells that binds to LFA3, a cell surface protein expressed on e.g., antigen-presenting cells. CD2 has an important role in the formation and organization of the immunological synapse that is formed between T cells and antigen-presenting cells upon cell-cell conjugation and associated intracellular signaling. CD2 expression is upregulated on memory T cells as well as activated T cells and plays an important role in activation of memory T cells despite the coexistence of several other costimulatory pathways. Anti-CD2 monoclonal antibodies have been shown to induce immune modulatory effectsin vitroand clinical studies have proven the safety and efficacy of CD2-targeting biologics. Investigators have highlighted that the lack of attention to the CD2/LFA3 costimulatory pathway is amissed opportunity. Overall, CD2 is an attractive target for monoclonal antibodies intended for treatment of pathologies characterized by undesired T cell activation and offers an avenue to more selectively target memory T cells while favoring immune regulation.
引用
收藏
页数:14
相关论文
共 162 条
  • [1] Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease
    Adkins, Douglas
    Ratanatharathorn, Voravit
    Yang, Harry
    White, Barbara
    [J]. TRANSPLANTATION, 2009, 88 (02) : 198 - 202
  • [2] Practical NK cell phenotyping and variability in healthy adults
    Angelo, Laura S.
    Banerjee, Pinaki P.
    Monaco-Shawver, Linda
    Rosen, Joshua B.
    Makedonas, George
    Forbes, Lisa R.
    Mace, Emily M.
    Orange, Jordan S.
    [J]. IMMUNOLOGIC RESEARCH, 2015, 62 (03) : 341 - 356
  • [3] A SOLUBLE MULTIMERIC RECOMBINANT CD2 PROTEIN IDENTIFIES CD48 AS A LOW AFFINITY LIGAND FOR HUMAN CD2 - DIVERGENCE OF CD2 LIGANDS DURING THE EVOLUTION OF HUMANS AND MICE
    ARULANANDAM, ARN
    MOINGEON, P
    CONCINO, MF
    RECNY, MA
    KATO, K
    YAGITA, H
    KOYASU, S
    REINHERZ, EL
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (05) : 1439 - 1450
  • [4] The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse
    Badour, K
    Zhang, JY
    Shi, F
    McGavin, MKH
    Rampersad, V
    Hardy, LA
    Field, D
    Siminovitch, KA
    [J]. IMMUNITY, 2003, 18 (01) : 141 - 154
  • [5] CD2 Costimulation Reveals Defective Activity by Human CD4+CD25hi Regulatory Cells in Patients with Multiple Sclerosis
    Baecher-Allan, Clare M.
    Costantino, Cristina M.
    Cvetanovich, Gregory L.
    Ashley, Charles W.
    Beriou, Gaelle
    Dominguez-Villar, Margarita
    Hafler, David A.
    [J]. JOURNAL OF IMMUNOLOGY, 2011, 186 (06) : 3317 - 3326
  • [6] Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
    Bartlett, Nancy L.
    Wilson, Wyndham H.
    Jung, Sin-Ho
    Hsi, Eric D.
    Maurer, Matthew J.
    Pederson, Levi D.
    Polley, Mei-Yin C.
    Pitcher, Brandelyn N.
    Cheson, Bruce D.
    Kahl, Brad S.
    Friedberg, Jonathan W.
    Staudt, Louis M.
    Wagner-Johnston, Nina D.
    Blum, Kristie A.
    Abramson, Jeremy S.
    Reddy, Nishitha M.
    Winter, Jane N.
    Chang, Julie E.
    Gopal, Ajay K.
    Chadburn, Amy
    Mathew, Susan
    Fisher, Richard I.
    Richards, Kristy L.
    Schoder, Heiko
    Zelenetz, Andrew D.
    Leonard, John P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (21) : 1790 - +
  • [7] The SH3 domain of p56(lck) binds to proline-rich sequences in the cytoplasmic domain of CD2
    Bell, GM
    Fargnoli, J
    Bolen, JB
    Kish, L
    Imboden, JB
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) : 169 - 178
  • [8] Safety and pharmacodynamics of anti-CD2 monoclonal antibody treatment in cynomolgus macaques - an experimental study
    Berglund, Erik
    Alonso-Guallart, Paula
    Danton, Makenzie
    Sellberg, Felix
    Binder, Christian
    Frobom, Robin
    Berglund, David
    Llore, Nathaly
    Sakai, Hiroshi
    Iuga, Alina
    Ekanayake-Alper, Dilrukshi
    Reimann, Keith A.
    Sachs, David H.
    Sykes, Megan
    Griesemer, Adam
    [J]. TRANSPLANT INTERNATIONAL, 2020, 33 (01) : 98 - 107
  • [9] NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs
    Beziat, Vivien
    Liu, Lisa L.
    Malmberg, Jenny-Ann
    Ivarsson, Martin A.
    Sohlberg, Ebba
    Bjorklund, Andreas T.
    Retiere, Christelle
    Sverremark-Ekstrom, Eva
    Traherne, James
    Ljungman, Per
    Schaffer, Marie
    Price, David A.
    Trowsdale, John
    Michaelsson, Jakob
    Ljunggren, Hans-Gustaf
    Malmberg, Karl-Johan
    [J]. BLOOD, 2013, 121 (14) : 2678 - 2688
  • [10] CRYSTAL-STRUCTURE OF THE EXTRACELLULAR REGION OF THE HUMAN CELL-ADHESION MOLECULE CD2 AT 2.5-ANGSTROM RESOLUTION
    BODIAN, DL
    JONES, EY
    HARLOS, K
    STUART, DI
    DAVIS, SJ
    [J]. STRUCTURE, 1994, 2 (08) : 755 - 766